Supplementary Table 1: FDA approval of checkpoint inhibitors for advanced NSCLC Generic name FDA approval Alternate Names Second-Line Nivolumab (q2 weekly) PD-L1 unselected ONO-4538, BMS-936558, MDX1106 squamous (March 4, 2015) PD-1 inhibitor non-squamous (October 9, 2015) BMS Pembrolizumab (q3 weekly) PD-L1 selected regardless of histology Lambrolizumab, MK-3475 PD-L1+ (October 2, 2015) ≥50% PD-1 Inhibitor PD-L (October 24, 2016) ≥1% Merck Atezolizumab (q3 weekly) PD-L1 unselected MPDL3280A regardless of histology PD-L1 inhibitor (October 18, 2016) Roche First Line Pembrolizumab (q3 weekly) PD-L1 selected regardless of histology Lambrolizumab, MK-3475 PD-L1+ (October 24, 2016) PD-1 Inhibitor ≥50% NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; Programmed death-ligand 1(-positive)
Supplementary Table 1: FDA approval of checkpoint inhibitors for advanced NSCLC Generic name Alternate Names FDA approval Second-Line Nivolumab (q2 weekly) ONO-4538, BMS-936558, MDX1106 PD-1 inhibitor BMS PD-L1 unselected squamous (March 4, 2015) non-squamous (October 9, 2015) Pembrolizumab (q3 weekly) Lambrolizumab, MK-3475 PD-1 Inhibitor Merck PD-L1 selected regardless of histology ≥50% PD-L1+ (October 2, 2015) ≥1% PD-L (October 24, 2016) Atezolizumab (q3 weekly) MPDL3280A PD-L1 inhibitor Roche PD-L1 unselected regardless of histology (October 18, 2016) First Line Pembrolizumab (q3 weekly) Lambrolizumab, MK-3475 PD-1 Inhibitor PD-L1 selected regardless of histology ≥50% PD-L1+ (October 24, 2016) NSCLC, non-small cell lung cancer; PD-1, programmed cell death protein 1; Programmed death-ligand 1(-positive)
1-s2.0-S030573721830015X-mmc1.docx